Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus standard therapy in adult pulmonary tuberculosis
ChiCTR2500105538Phase 4Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nintedanib in pulmonary tuberculosis (TB) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoints: Median time to sputum culture conversion, Vital signs and 2 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2500105538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105538.